<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01354275</url>
  </required_header>
  <id_info>
    <org_study_id>BH532008</org_study_id>
    <secondary_id>KA04/104</secondary_id>
    <nct_id>NCT01354275</nct_id>
  </id_info>
  <brief_title>In Vitro Fertilization Outcomes of Two Treatment Protocols in Women With Polycystic Ovary Syndrome</brief_title>
  <acronym>PCOS and ivf</acronym>
  <official_title>IVF/ICSI Outcomes of OCP Plus GnRH Agonist Protocol Versus OCP Plus GnRH Antagonist Fixed Protocol in Women With PCOS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bulent Haydardedeoglu</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Baskent University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Outcomes of IVF/ICSI cycles of women with PCOS undergoing Gonadotropin Releasing Hormone
      (GnRH) agonist and GnRH Antagonist fixed protocol.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Women with PCOS undergoing IVF/ICSI cycles will be evaluated by two different protocols. One
      arm of the study includes oral contraceptive plus GnRH agonist protocol with 150 IU FSH
      (standard dose) and second arm includes oral contraceptive plus GnRH Antagonist with 150 IU
      FSH dose and fixed 6th day starting of GnRH Antagonist.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    . The trial would be continued if there was a difference of â‰¥3 % between trial arms. However,
    the difference between ongoing pregnancy rates was &lt;1 %
  </why_stopped>
  <start_date>March 2009</start_date>
  <completion_date type="Actual">June 2011</completion_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ongoing pregnancy rates</measure>
    <time_frame>March 2009 to June 2011</time_frame>
    <description>Ongoing pregnancy rates measured in OCP plus GnRH Agonist and OCP plus GnRH Antagonist cycles in women with PCOS</description>
  </primary_outcome>
  <primary_outcome>
    <measure>clinical pregnancy rate</measure>
    <time_frame>from march 2009 to july 2011</time_frame>
    <description>To evaluate the clinical pregnancy rates of both study arms</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total gonadotropin use</measure>
    <time_frame>From march 2009 to June 2011</time_frame>
    <description>Total gonadotropin use of both study arms</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>OHSS rates</measure>
    <time_frame>from march 2009 to july 2011</time_frame>
    <description>OHSS rates in both study groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total ongoing pregnancy rate</measure>
    <time_frame>from march 2009 to june 2011</time_frame>
    <description>Total ongoing pregnacy rates of per protocol group including freezing-thawing embryo transfer cycles.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">300</enrollment>
  <condition>PCOS GnRH Antagonist and GnRH Agonist IVF/ICSI Cycles</condition>
  <arm_group>
    <arm_group_label>GnRH Agonist</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>oral contraceptive pill and GnRH Agonist IVF/ICSI cycle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GnRH Agonist Arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oral contraceptive pill and day 21 GnRH agonist began, Day 3 of menstruation 150 IU FSH will be started. If 3 or more follicle reach &gt;17 mm hCG will be administered.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>To compare the IVF/ICSI outcomes of GnRH Antagonist cycle versus GnRH agonist cycle</intervention_name>
    <description>150 IU FSH dose and OCP plus GnRH Agonist (long luteal) IVF/ICSI cycle and 150 IU FSH dose and OCP plus GnRH Antagonist (Fixed protocol) IVF/ICSI Cycle</description>
    <arm_group_label>GnRH Agonist</arm_group_label>
    <arm_group_label>GnRH Agonist Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>GnRH Antagonist</intervention_name>
    <description>GnRH Antagonist cycle; 150 IU FSH and sixth day Antagonist will be administered</description>
    <arm_group_label>GnRH Agonist Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  PCOS women undergoing ICSI cycles

          -  All women will be administered 150 IU rec FSH

        Exclusion Criteria:

          -  Women having other endocrinopathies

          -  women older than 35

          -  third IVF/ICSI cycles

          -  previous and current use of metformin
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bulent Haydardedeoglu, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Baskent University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Bulent Haydardedeoglu</name>
      <address>
        <city>Adana</city>
        <zip>01120</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>February 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 12, 2011</study_first_submitted>
  <study_first_submitted_qc>May 13, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 16, 2011</study_first_posted>
  <last_update_submitted>February 1, 2012</last_update_submitted>
  <last_update_submitted_qc>February 1, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 3, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Baskent University</investigator_affiliation>
    <investigator_full_name>Bulent Haydardedeoglu</investigator_full_name>
    <investigator_title>IVF/ICSI Outcomes of OCP Plus GnRH Agonist Protocol Versus OCP Plus GnRH Antagonist Fixed Protocol in Women With PCOS: A Randomized Controlled Trial</investigator_title>
  </responsible_party>
  <keyword>PCOS</keyword>
  <keyword>IVF/ICSI</keyword>
  <keyword>Clinical Pregnancy rates</keyword>
  <keyword>GnRH Antagonist</keyword>
  <keyword>GnRH Agonist</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polycystic Ovary Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prolactin Release-Inhibiting Factors</mesh_term>
    <mesh_term>Deslorelin</mesh_term>
    <mesh_term>Triptorelin Pamoate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

